[{"orgOrder":0,"company":"Lepu Biopharma","sponsor":"ArriVent","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"CHINA","productType":"Antibody-drug Conjugate","year":"2025","type":"Licensing Agreement","leadProduct":"MRG007","moa":"Undisclosed","graph1":"Oncology","graph2":"Preclinical","graph3":"Lepu Biopharma","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Lepu Biopharma \/ ArriVent","highestDevelopmentStatusID":"4","companyTruncated":"Lepu Biopharma \/ ArriVent"},{"orgOrder":0,"company":"Lepu Biopharma","sponsor":"Hanx Biopharmaceutical","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"CHINA","productType":"Antibody","year":"2022","type":"Inapplicable","leadProduct":"Pucotenlimab","moa":"PD-1","graph1":"Oncology","graph2":"Approved FDF","graph3":"Lepu Biopharma","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Lepu Biopharma \/ Hanx Biopharmaceutical","highestDevelopmentStatusID":"15","companyTruncated":"Lepu Biopharma \/ Hanx Biopharmaceutical"}]

Find Clinical Drug Pipeline Developments & Deals by Lepu Biopharma

Menu
Xls
Filters Filter
×
FILTER:
filter
Company Name
    filter

    Year

      filter

      DEALS // DEV.

        filter

        Country

          filter
          Sponsor
            filter

            Therapeutic Area

              filter

              Study Phase

                filter

                Deal Type

                  filter

                  Product Type

                    filter

                    Dosage Form

                      filter

                      Lead Product

                        filter

                        Target

                          Loading...

                          Therapeutic Area by Lead Product

                          Study Phase by Lead Product

                          Company by Lead Product

                          Top Deals by Deal Size (USD bn)

                          01

                          Interphex
                          Not Confirmed
                          Interphex
                          Not Confirmed

                          Details :

                          Product Name : MRG007

                          Product Type : Antibody-drug Conjugate

                          Upfront Cash : $47.0 million

                          January 21, 2025

                          Lead Product(s) : MRG007

                          Therapeutic Area : Oncology

                          Highest Development Status : Preclinical

                          Sponsor : ArriVent

                          Deal Size : $1,207.0 million

                          Deal Type : Licensing Agreement

                          blank

                          02

                          Interphex
                          Not Confirmed
                          Interphex
                          Not Confirmed

                          Details :

                          Product Name : Puyouheng

                          Product Type : Antibody

                          Upfront Cash : Inapplicable

                          July 25, 2022

                          Lead Product(s) : Pucotenlimab

                          Therapeutic Area : Oncology

                          Highest Development Status : Approved FDF

                          Sponsor : Hanx Biopharmaceutical

                          Deal Size : Inapplicable

                          Deal Type : Inapplicable

                          blank